Mandate

Vinge advises Altor, the founders and the other sellers in connection with the divestment of a majority share in Eleda to Bain Capital

Vinge advises Altor Funds (“Altor”), the founders and the other sellers in connection with Bain Capital Private Equity (“Bain Capital”), a leading global private investment firm, acquiring a controlling stake in Eleda from Altor, which will reinvest a minority share. Eleda’s founders, Johan Halvardsson and Peter Condrup, and senior executives in Eleda will also reinvest a substantial share. Through the transaction, Altor, Eleda and Bain Capital establish a partnership for future expansion.

Headquartered in Stockholm and with approximately 3,000 employees, Eleda is a leading Nordic infrastructure development and services provider. The company is the market leader within several segments, many addressing the need of the green transition, including water and sewerage, power distribution, district heating, roads, data centres, railways, and electric vehicle charging stations. Eleda’s decentralised operating model allows its group companies to deliver the highest quality to their customers with the optimal mix of local presence and the resources of a larger organization.

The transaction is subject to regulatory approvals.

Vinge’s team consisted mainly of Christina Kokko, Johanna Wiberg, Carl Fredrik Wachtmeister, Ellen Flygt, Philip Moré, Jonatan Stentorp, Jonas Johansson, Nina Gransäter and Johan Gavelin (M&A), Louise Brorsson Salomon and Jolinn Uhlin (Banking and Finance), Martin Johansson and Hedvig Josefson (EU Regulatory), Emy Rydén, Emelie Schoning, Gabriella Balbo, Emma Emsjö, Christoffer Widström and Fanny Askelöf (Transaction Support Coordinators).

Read the client’s press release           

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025